Select Page

Press Release

Rapid Dose Therapeutics to Participate in the Venture Mentoring Services Program in Partnership with Maryland Tech Council and Canada’s Trade Commissioner Service

BURLINGTON, Ontario – September 29, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is one of five Canadian companies accepted into this year’s Venture Mentoring Services program offered by the Maryland Tech Council (MTC) in partnership with the Canadian Trade Commissioner Service in Washington, DC.

The MTC’s Venture Mentoring Services program is a comprehensive, team mentor approach with an ultimate goal to help a company grow faster by providing advice and fostering introductions with federal laboratories, academic and research institutions, biopharmaceutical companies and investors in the BioHealth Capital Region (Washington DC, Maryland, Virginia).

“It is an honour to have been selected for this prestigious Mentoring Services program, which will offer us a unique opportunity to introduce our oral thin film technology to top-tier academic and government agencies in the United States by collaborating with our mentors,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “We are keen to explore the deep expertise our mentors have in helping companies grow and will use the next six months to work with them to strategically set ourselves up for continued success.”

The Company is keen to continue advancing their ambitious plans related to the broad-scale commercialization of the oral thin film technology. RDT is currently working on a number of key initiatives, including:

Global vaccination efforts – The flexibility of the oral thin film technology to deliver vaccines in a format that does not require sophisticated cold-chain storage or needles makes it a novel option to support global vaccination targets, a problem that has been identified as critical based on the experiences of the current COVID-19 pandemic.

Pharmaceutical applications – The oral thin film technology has been proven to deliver a wide range of active pharmaceutical ingredients and is currently being used by compounding pharmacies in medical and dental applications.

Nutraceutical and vitamin uses – RDT’s QuickStrip brand of vitamin and nutraceutical supplements are distributed and sold through multiple Canadian retail chains.

Over the next six months, the Company will have the opportunity to work with, collaborate and learn from the following three mentors who have been trained to use the well-established Massachusetts Institute of Technology (MIT) Venture Mentoring Services curriculum:

Jonathan Kay – Seasoned senior executive and trusted advisor to C-suite executives in the biotech, pharmaceuticals and medical devices sectors. Exerienced mentor with significant experience advising and supporting strategy development, implementation and commercialization to companies with innovations that help solve clinical and economic unmet neets in healthcare.

Steen Nissen – Results orientated leader in both start-up companies and global organizations and a proven track record of creating and managing strong and motivated teams. He has an in-depth understanding of building start-up companies, of technology development and commercialization, and business development. He has a truly global background with experience in North & South America, Europe, and China/Asia and he has worked extensively with business development in new and emerging markets.

Seth Silber – Focuses on advancing clients in the pharmaceutical and healthcare markets, including support with patent settlements, M&A and anticompetitive conduct. He was previously with the Federal Trade Commission.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit

For more information:

Mark Upsdell, CEO Dara Willis
Investor Contact Media Contact
416-477-1052 416-836-9272

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws.
Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks.  Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.



Back to press releases page